Research Progress on Factors of Early Bioprostheses Degeneration_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

LIUXin-yu ,  LIUHong-yu

Department of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150010, P. R. China;

Corresponding author：

LIUHong-yu, Email: hyliu1963@163.com

Keywords：

Bioprostheses (BP); Structural valve degeneration (SVD); Early valve degeneration (EVD)

DOI：

10.7507/1007-4848.20150262

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Valve replacement is one of the way to treat valvular heart disease. Valve replacement with bioprostheses, which occurs low rate of bleeding and thromboembolism events, needs no lifelong anticoagulation. However, the life of bioprostheses is limited. Leaflet tear, leaf calcification, and artificial valve infective endocarditis may occur with using a bioprostheses These adverse events appear early to some patients who fail to achieve the expected service life of bioprostheses. This review mainly summarizes factors influencing early valve degeneration(EVD) of bioprostheses to provide suggestion in clinic.

Citation： LIUXin-yu, LIUHong-yu. Research Progress on Factors of Early Bioprostheses Degeneration. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2015, 22(11): 1060-1063. doi: 10.7507/1007-4848.20150262 Copy

1.	Barnett SD,Ad N.Surgery for aortic and mitral valve disease in the United States:A trend of change in surgical practice between 1998 and 2005.Thorac Cardiovasc Surg,2009,137(6):1422-1429.
2.	Ruel M,Chan V,Bédard P,et al.Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age.Circulation,2007,116(11 Suppl):I294-I300.
3.	Wei X,Yi W,Chen W,et al.Clinical outcomes with the epicholorohydrin-modified porcine aortic heart valve:A 15-year follow-up.Ann Thorac Surg,2010,89(5):1417-1424.
4.	McClure RS1,Narayanasamy N,Wiegerinck E,et al.Late outcomes for aortic valve replacement with the carpentier-edwards pericardial bioprosthesis:up to 17-year follow-up in 1,000 patients.Ann Thorac Surg,2010,89(5):1410-1416.
5.	Pupello DF,Bessone LN,Hiro SP,et al.The Carpentier-Edwards bioprosthesis:a comparative study analyzing failure rates by age.J Card Surg,1988,3(3 Suppl):369-374.
6.	Joshi V,Prosser K,Richens D.Early prosthetic valve degeneration with Mitroflow aortic valves:determination of incidence and risk factors.J Interact Cardiovasc Thorac Surg,2014,19(1):36-40.
7.	Nollert G,Miksch J,Kreuzer E,et al.Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement.J Thorac Cardiovasc Surg,2003,126(4):965-968.
8.	Briand M,Pibarot P,Després JP,et al.Metabolic syndrome is associated with faster degeneration of bioprosthetic valves.Circulation,2006,114(1 Suppl):I512-I517.
9.	Bonow RO,Grundy SM,Howard B,et al.Prevention conference VI:diabetes and cardiovascular disease:executive summary conference proceeding for healthcare professionals from a special writing group of the american heart association.Circulation,2002,105(18):2231-2239.
10.	Katz R,Budoff MJ,Takasu J,et al.Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression:the Multi-Ethnic Study of Atherosclerosis(MESA).Diabetes,2009,58(4):813-819.
11.	Lorusso R,Gelsomino S,LucàF,et al.Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve:results from a propensity score-matched Italian multicenter study.Circulation,2012,125(4):604-614.
12.	Yeghiazaryan K,Bauriedel G,Schild HH,et al.Prediction of degeneration of native and bioprosthetic aortic valves:issue-related particularities of diabetes mellitus.Infect Disord Drug Targets,2008,8(2):88-99.
13.	Halkos ME,Kilgo P,Lattouf OM,et al.The effect of diabetes mellitus on in-hospital and long-term outcomes after heart valve operations.Ann Thorac Surg,2010,90(1):124-130.
14.	Mohler ER 3rd.Are atherosclerotic processes involved in aorticvalve calcification?Lancet,2000,356(9229):524-525.
15.	Demer LL.Cholesterol in vascular and valvular calcification.Circulation,2001,104(16):1881-1883.
16.	Bild D,Folsom A,Lowe L,et al.Prevalence and correlates of coronary calcification in black and white young adults:the coronary artery risk development in young adults(CARDIA)study.Arterioscler Thromb Vasc Biol,2001,21(5):852-857.
17.	Farivar RS,Cohn LH.Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation.Thorac Cardiovasc Surg,2003,126(4):969-975.
18.	Briand M,Pibarot P,Després JP,et al.Metabolic syndrome is associated with faster degeneration of bioprosthetic valves.Circulation,2006,114(1 Suppl):I512-I527.
19.	Shetty R,Girerd N,CôtéN,et al.Elevated proportion of small,dense low-density lipoprotein particles and lower adiponectin blood levels predict early structural valve degeneration of bioprostheses.Cardiology,2012,121(1):20-26.
20.	Mahjoub H1,Mathieu P,Sénéchal M,et al.ApoB/ApoA-I ratio is associated with increased risk of bioprosthetic valve degeneration.Am Coll Cardiol,2013,61(7):752-761.
21.	Vyavahare NR,Jones PL,Hirsch D,et al.Prevention of glutaraldehydefixed bioprosthetic heart valve calcification by alcohol pretreatment:further mechanistic studies.Heart Valve Dis,2000,9(4):561-566.
22.	Parhami F,Morrow AD,Balucan J,et al.Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation.A possible explanation for the paradox of arterial calcification in osteoporotic patients.Arterioscler Thromb Vasc Biol,1997,17(4):680-687.
23.	Chin H,Harrison E,Blankenhorn D,et al.Lipids in silicone rubber valve prostheses after human implantation.Circulation,1971,43(5 Suppl):I51-I56.
24.	Bellamy M,Pellika P,Klarish K,et al.Association of cholesterol levels,hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment,and progression of aortic stenosis in the community.Am Coll Cardiol,2002,40(10):1723-1730.
25.	Novaro GM,Tiong IY,Pearce GL,et al.Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis.Circulation,2001,104(18):2205-2209.
26.	Aronow W,Ahn C,Kronzon I,et al.Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons.Am Cardiol,2001,88(6):693-695.
27.	Antonini-Canterin F,Zuppiroli A,Popescu BA,et al.Effect of statins on the progression of bioprosthetic aortic valve degeneration.Am Cardiol,2003,92(12):1479-1482.
28.	Colli A,Gherli T,Mestres CA,et al.Degeneration of native and tissue prosthetic valve in aortic position:do statins play an effective role in prevention?Int Cardiol,2007,116(2):144-152.
29.	Schoen FJ,Levy RJ.Pathology of substitute heart valves:new concept and developments.Card Surg,1994,9(2 Suppl):222-227.
30.	Ito Y,Ohuchi S,Okubo T,et al.Early calcification of bioprosthetic valve in a hemodialysis patient with secondary hyperparathyroidism;report of a case.Kyobu Geka,2013,66(9):833-836.
31.	Iyer A,Malik P,Prabha R,et al.Early postoperative bioprosthetic valve calcification.Heart Lung Circ,2013,22(10):873-874.
32.	Lerman A,McConnell JP.Lipoprotein-associated phospholipase A2:a risk marker or a risk factor?Am J Cardiol,2008,101(12A):11F-22F.
33.	Mahmut A1,Mahjoub H,Boulanger MC,et al.Lp-PLA2 is associated with structural valve degeneration of bioprostheses.Eur J Clin Invest,2014,44(2):136-145.
34.	Asopa S,Iyengar S,Velissaris T,et al.Early prosthetic valve failure in a patient with rheumatoid arthritis.J Card Surg,2009,24(1):85-87.
35.	Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Am Coll Cardiol,2014,63(22):e57-e185.
36.	Yankah CA,Schubel J,Buz S,et al.Seventeen-year clinical results of 1,037 Mitroflow pericardial heart valve prostheses in the aortic position.Heart Valve Dis,2005,14(2):172-179.
37.	Banbury MK,Cosgrove DM,White JA,et al.Age and Valve Size Effect on the Long-Term Durability of the Carpentier-Edwards Aortic Pericardial Bioprosthesis.Ann Thorac Surg,2001,72(3):753-757.
38.	Flameng W,Herregods MC,Vercalsteren M,et al.Prosthesispatient mismatch predicts structural valve degeneration in bioprosthetic heart valves.Circulation,2010,121(19):2123-2129.
39.	Sabbah HN,Hamid MS,Stein PD.Mechanical factors in the degeneration of porcine bioprosthetic valves:an overview.Card Surg,1989,4(4):302-309.
40.	Pibarot P,Dumesnil JG.Prosthetic heart valves:selection of the optimal prosthesis and long-term management.Circulation,2009,119(7):1034-1048.
41.	Shahzeb KM,Imran BF,Asadullah K,et al.Prosthesis-patient mismatch causes a significantly increased risk of operative mortality in aortic valve replacement.Heart Surg Forum,2014,17(3):E127-E131.

1. Barnett SD,Ad N.Surgery for aortic and mitral valve disease in the United States:A trend of change in surgical practice between 1998 and 2005.Thorac Cardiovasc Surg,2009,137(6):1422-1429.
2. Ruel M,Chan V,Bédard P,et al.Very long-term survival implications of heart valve replacement with tissue versus mechanical prostheses in adults <60 years of age.Circulation,2007,116(11 Suppl):I294-I300.
3. Wei X,Yi W,Chen W,et al.Clinical outcomes with the epicholorohydrin-modified porcine aortic heart valve:A 15-year follow-up.Ann Thorac Surg,2010,89(5):1417-1424.
4. McClure RS1,Narayanasamy N,Wiegerinck E,et al.Late outcomes for aortic valve replacement with the carpentier-edwards pericardial bioprosthesis:up to 17-year follow-up in 1,000 patients.Ann Thorac Surg,2010,89(5):1410-1416.
5. Pupello DF,Bessone LN,Hiro SP,et al.The Carpentier-Edwards bioprosthesis:a comparative study analyzing failure rates by age.J Card Surg,1988,3(3 Suppl):369-374.
6. Joshi V,Prosser K,Richens D.Early prosthetic valve degeneration with Mitroflow aortic valves:determination of incidence and risk factors.J Interact Cardiovasc Thorac Surg,2014,19(1):36-40.
7. Nollert G,Miksch J,Kreuzer E,et al.Risk factors for atherosclerosis and the degeneration of pericardial valves after aortic valve replacement.J Thorac Cardiovasc Surg,2003,126(4):965-968.
8. Briand M,Pibarot P,Després JP,et al.Metabolic syndrome is associated with faster degeneration of bioprosthetic valves.Circulation,2006,114(1 Suppl):I512-I517.
9. Bonow RO,Grundy SM,Howard B,et al.Prevention conference VI:diabetes and cardiovascular disease:executive summary conference proceeding for healthcare professionals from a special writing group of the american heart association.Circulation,2002,105(18):2231-2239.
10. Katz R,Budoff MJ,Takasu J,et al.Relationship of metabolic syndrome with incident aortic valve calcium and aortic valve calcium progression:the Multi-Ethnic Study of Atherosclerosis(MESA).Diabetes,2009,58(4):813-819.
11. Lorusso R,Gelsomino S,LucàF,et al.Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve:results from a propensity score-matched Italian multicenter study.Circulation,2012,125(4):604-614.
12. Yeghiazaryan K,Bauriedel G,Schild HH,et al.Prediction of degeneration of native and bioprosthetic aortic valves:issue-related particularities of diabetes mellitus.Infect Disord Drug Targets,2008,8(2):88-99.
13. Halkos ME,Kilgo P,Lattouf OM,et al.The effect of diabetes mellitus on in-hospital and long-term outcomes after heart valve operations.Ann Thorac Surg,2010,90(1):124-130.
14. Mohler ER 3rd.Are atherosclerotic processes involved in aorticvalve calcification?Lancet,2000,356(9229):524-525.
15. Demer LL.Cholesterol in vascular and valvular calcification.Circulation,2001,104(16):1881-1883.
16. Bild D,Folsom A,Lowe L,et al.Prevalence and correlates of coronary calcification in black and white young adults:the coronary artery risk development in young adults(CARDIA)study.Arterioscler Thromb Vasc Biol,2001,21(5):852-857.
17. Farivar RS,Cohn LH.Hypercholesterolemia is a risk factor for bioprosthetic valve calcification and explantation.Thorac Cardiovasc Surg,2003,126(4):969-975.
18. Briand M,Pibarot P,Després JP,et al.Metabolic syndrome is associated with faster degeneration of bioprosthetic valves.Circulation,2006,114(1 Suppl):I512-I527.
19. Shetty R,Girerd N,CôtéN,et al.Elevated proportion of small,dense low-density lipoprotein particles and lower adiponectin blood levels predict early structural valve degeneration of bioprostheses.Cardiology,2012,121(1):20-26.
20. Mahjoub H1,Mathieu P,Sénéchal M,et al.ApoB/ApoA-I ratio is associated with increased risk of bioprosthetic valve degeneration.Am Coll Cardiol,2013,61(7):752-761.
21. Vyavahare NR,Jones PL,Hirsch D,et al.Prevention of glutaraldehydefixed bioprosthetic heart valve calcification by alcohol pretreatment:further mechanistic studies.Heart Valve Dis,2000,9(4):561-566.
22. Parhami F,Morrow AD,Balucan J,et al.Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation.A possible explanation for the paradox of arterial calcification in osteoporotic patients.Arterioscler Thromb Vasc Biol,1997,17(4):680-687.
23. Chin H,Harrison E,Blankenhorn D,et al.Lipids in silicone rubber valve prostheses after human implantation.Circulation,1971,43(5 Suppl):I51-I56.
24. Bellamy M,Pellika P,Klarish K,et al.Association of cholesterol levels,hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment,and progression of aortic stenosis in the community.Am Coll Cardiol,2002,40(10):1723-1730.
25. Novaro GM,Tiong IY,Pearce GL,et al.Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis.Circulation,2001,104(18):2205-2209.
26. Aronow W,Ahn C,Kronzon I,et al.Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons.Am Cardiol,2001,88(6):693-695.
27. Antonini-Canterin F,Zuppiroli A,Popescu BA,et al.Effect of statins on the progression of bioprosthetic aortic valve degeneration.Am Cardiol,2003,92(12):1479-1482.
28. Colli A,Gherli T,Mestres CA,et al.Degeneration of native and tissue prosthetic valve in aortic position:do statins play an effective role in prevention?Int Cardiol,2007,116(2):144-152.
29. Schoen FJ,Levy RJ.Pathology of substitute heart valves:new concept and developments.Card Surg,1994,9(2 Suppl):222-227.
30. Ito Y,Ohuchi S,Okubo T,et al.Early calcification of bioprosthetic valve in a hemodialysis patient with secondary hyperparathyroidism;report of a case.Kyobu Geka,2013,66(9):833-836.
31. Iyer A,Malik P,Prabha R,et al.Early postoperative bioprosthetic valve calcification.Heart Lung Circ,2013,22(10):873-874.
32. Lerman A,McConnell JP.Lipoprotein-associated phospholipase A2:a risk marker or a risk factor?Am J Cardiol,2008,101(12A):11F-22F.
33. Mahmut A1,Mahjoub H,Boulanger MC,et al.Lp-PLA2 is associated with structural valve degeneration of bioprostheses.Eur J Clin Invest,2014,44(2):136-145.
34. Asopa S,Iyengar S,Velissaris T,et al.Early prosthetic valve failure in a patient with rheumatoid arthritis.J Card Surg,2009,24(1):85-87.
35. Nishimura RA,Otto CM,Bonow RO,et al.2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.Am Coll Cardiol,2014,63(22):e57-e185.
36. Yankah CA,Schubel J,Buz S,et al.Seventeen-year clinical results of 1,037 Mitroflow pericardial heart valve prostheses in the aortic position.Heart Valve Dis,2005,14(2):172-179.
37. Banbury MK,Cosgrove DM,White JA,et al.Age and Valve Size Effect on the Long-Term Durability of the Carpentier-Edwards Aortic Pericardial Bioprosthesis.Ann Thorac Surg,2001,72(3):753-757.
38. Flameng W,Herregods MC,Vercalsteren M,et al.Prosthesispatient mismatch predicts structural valve degeneration in bioprosthetic heart valves.Circulation,2010,121(19):2123-2129.
39. Sabbah HN,Hamid MS,Stein PD.Mechanical factors in the degeneration of porcine bioprosthetic valves:an overview.Card Surg,1989,4(4):302-309.
40. Pibarot P,Dumesnil JG.Prosthetic heart valves:selection of the optimal prosthesis and long-term management.Circulation,2009,119(7):1034-1048.
41. Shahzeb KM,Imran BF,Asadullah K,et al.Prosthesis-patient mismatch causes a significantly increased risk of operative mortality in aortic valve replacement.Heart Surg Forum,2014,17(3):E127-E131.

Previous Article
Research Progress of Flail Chest with Pulmonary Contusion
Next Article
Unplanned Extended Resection for Locally Advanced Non-small Cell Lung Cancer: A Retrospective Analysis

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research Progress on Factors of Early Bioprostheses Degeneration

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content